Results 191 to 200 of about 696,855 (303)

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Cardiovascular toxicity induced by immune checkpoint inhibitors: mechanisms linking immune dysregulation and myocardial fibrosis. [PDF]

Am J Clin Exp Immunol
Wang D, Jia BK, Li ZY, Qiao Q, Cheng L, Zhang LH, Ye XR, Zhang HL, Zhang JJ.   +8 more
europepmc   +1 more source

MYC promotes myocardial fibrosis via METTL1-mediated m7G modification of HILPDA. [PDF]

Biol Direct
Liu Y, Li K, Chen Y, Xia H.
europepmc   +1 more source

Myocardial fibrosis and hyperaldosteronism [PDF]

European Heart Journal, 1996
J. E. SANDERSON, C. S. COCKRAM, C. M. YU, S. E. CAMPBELL, K. T. WEBER   +4 more
openaire   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Impact of Myocardial Fibrosis and Female Sex on Life-Threatening Arrhythmias and Sudden Cardiac Death in Mitral Valve Prolapse. [PDF]

Circ Cardiovasc Imaging
Darwish A, Nguyen DT, Songsangjinda T, Kitkungvan D, Saeed M, Bersali A, Qamar F, Potapenko M, Dadabhoy F, Tastet L, El-Tallawi KC, Lawrie G, Valderrábano M, Delling FN, Graviss EA, Kim RJ, Shah DJ.   +16 more
europepmc   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Discovery of novel biomarkers associated with myocardial fibrosis in chimpanzees (<i>Pan troglodytes</i>). [PDF]

Front Vet Sci
Jarvis Martin R, Baiker K, Moittié S, Dobbs P, White K, Liptovszky M, Grant MM.   +6 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Ferroptosis in Myocardial Fibrosis: Mechanisms and Therapeutic Insights. [PDF]

Antioxidants (Basel)
Lin X, Li W, Ye J, Li L.
europepmc   +1 more source